title: Overview: progression-free survival as an endpoint in clinical trials with solid tumors.
abstract: Progression-free survival (PFS) is increasingly used as an important and even a primary endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors for both practical and clinical considerations. Although in its simplest form, PFS is the time from randomization to a predefined endpoint, there are many factors that can influence the exact moment of when disease progression is recorded. In this overview, we review the circumstances that can devalue the use of PFS as a primary endpoint and attempt to provide a pathway for a future desired state when PFS will become not just a secondary alternative to overall survival but rather an endpoint of choice.
authors.affiliation: Imaging Endpoints Core Lab, Scottsdale, Arizona, USA.
authors.forename: Ronald L
authors.initials: RL
authors.lastname: Korn
authors.forename: John J
authors.initials: JJ
authors.lastname: Crowley
mesh_terms: D018450:Disease Progression; D018572:Disease-Free Survival; D023381:Endpoint Determination / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*; D017063:Outcome Assessment, Health Care / Q000379:methods*; D016032:Randomized Controlled Trials as Topic